BOXMEER, The Netherlands — October 23, 2025 — MSD Animal Health, a global leader in veterinary biopharmaceutical innovation, announced new data demonstrating that intranasal vaccination against bovine coronavirus using BOVILLIS® NASALGEN®-C (Lyophilisate and Solvent for Suspension for Cattle) significantly improves production outcomes in veal calves. The findings highlight that early intranasal administration of the vaccine results in enhanced immune response, reduced viral shedding, and better respiratory health, ultimately leading to improved growth performance. This milestone underscores MSD Animal Health’s commitment to advancing preventive veterinary medicine through science-backed, GxP-aligned research and innovation.
Science Significance
The study demonstrates that BOVILLIS® NASALGEN®-C, a live attenuated intranasal vaccine, provides robust protection against bovine coronavirus, a major pathogen in the Bovine Respiratory Disease (BRD) complex. Administered from the first day of life, the vaccine stimulates local mucosal immunity in the upper respiratory tract, the primary entry site of infection. By reducing viral load and respiratory lesions, the vaccine effectively lowers disease severity and transmission. This advancement confirms the scientific importance of intranasal immunization as a preferred strategy for neonatal protection, particularly in high-density veal production systems. MSD Animal Health’s evidence-based findings further reinforce the role of precision vaccination programs designed in accordance with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) principles, ensuring data integrity and reproducibility.
Regulatory Significance
The new data strengthen the regulatory foundation supporting BOVILLIS® NASALGEN®-C across key animal health markets. MSD Animal Health’s research aligns with Good Manufacturing Practice (GMP) and Good Veterinary Practice (GVP) standards, demonstrating full compliance with regulatory expectations for vaccine safety, potency, and stability. The findings will support post-authorization surveillance and label expansions, reinforcing MSD’s transparency with authorities such as the European Medicines Agency (EMA) and equivalent bodies globally. The vaccine’s validation for use in young calves, along with its documented reduction in viral shedding, contributes directly to evidence-based licensing frameworks and One Health policy objectives. These regulatory milestones illustrate how science-driven compliance and data transparency underpin sustainable veterinary biopharma innovation.
Business Significance
Advertisement
The data affirm MSD Animal Health’s leadership in the bovine vaccine market, positioning BOVILLIS® NASALGEN®-C as a cornerstone product within its respiratory disease portfolio. The intranasal route not only enhances animal welfare through non-invasive administration but also supports labor efficiency and herd management cost savings — critical factors for commercial producers. Improved calf health outcomes translate to higher productivity, lower antibiotic reliance, and optimized growth rates, delivering measurable economic value to the livestock industry. From a business perspective, this scientific validation strengthens MSD Animal Health’s competitive edge and supports the company’s long-term strategy of integrating GxP excellence with sustainable animal health solutions. The alignment of science, compliance, and economic performance reinforces MSD’s position as a trusted global partner in the regulated veterinary biopharma sector.
Patients’ Significance
For animal caretakers and veterinarians, the intranasal vaccination of newborn calves offers both clinical and welfare benefits. The vaccine induces rapid-onset mucosal immunity, protecting calves during their most vulnerable early life stages. By preventing respiratory illness, the vaccine reduces stress, minimizes the need for therapeutic interventions, and improves overall animal welfare and growth consistency. This contributes to a healthier start for calves and greater confidence among producers that their livestock is protected under science-based preventive protocols. In the broader sense, effective vaccination programs like BOVILLIS® NASALGEN®-C also align with public health priorities by decreasing antimicrobial use and reducing the potential for resistance development — reflecting a One Health approach that benefits both animals and humans.
Policy Significance
The release of this data supports global animal health policy goals emphasizing preventive vaccination and responsible antimicrobial stewardship. Regulatory bodies and industry associations increasingly advocate for disease prevention through validated vaccines, and MSD Animal Health’s findings reinforce this direction. The demonstrated production and welfare improvements contribute to international frameworks promoting sustainable livestock management and biosecurity enhancement. Moreover, the vaccine’s compliance with Good Manufacturing Practice (GMP) standards illustrates how quality systems and science-driven oversight are critical to achieving policy-aligned health outcomes. By championing transparency, quality, and traceability, MSD Animal Health exemplifies how policy and compliance can converge with innovation to advance the global veterinary ecosystem.
The new data from MSD Animal Health underscore the clinical efficacy, safety, and economic value of BOVILLIS® NASALGEN®-C in preventing bovine coronavirus infections in veal calves. Through the integration of scientific innovation, regulatory compliance, and responsible biopharma practice, the company continues to set benchmarks for GxP-aligned animal health solutions. As the industry shifts toward preventive, welfare-driven, and sustainable livestock management, MSD’s latest achievement demonstrates how science-backed compliance and vaccine innovation can drive meaningful improvements in animal health, productivity, and global food security.
Source : MSD-Animal Health press release
